Alacris Theranostics

Alacris Theranostics is a privately held, revenue-generating service provider and diagnostics company operating at the intersection of genomics, oncology, and AI/machine learning. Its core offering is the Alacris-CMTA® platform, a deep comprehensive genomic profiling service that combines whole exome/genome sequencing with deep bulk transcriptomics for precision oncology diagnostics, operating within an ISO 15189:2024 accredited laboratory. Beyond its clinical diagnostics service, the company provides a full suite of scalable, end-to-end NGS and bioinformatics services for research and pharma, supported by a strong track record in EU-funded research consortia. Alacris is positioned as a specialized partner translating complex omics data into real-world benefits for personalized patient care and research discovery.

Alacris-CMTA® (Comprehensive Molecular Tumor Analysis) platform integrating deep bulk transcriptomics with whole exome or whole genome sequencing for deep comprehensive genomic profiling (Deep-CGP). Supported by proprietary bioinformatics software and operated within an ISO 15189:2024 accredited laboratory.

Alacris competes in a crowded field including large sequencing service CROs (e.g., Eurofins Genomics), specialized oncology diagnostics companies (e.g., Foundation Medicine, Tempus in the US), and academic core facilities. Its differentiation lies in its integrated deep transcriptomics approach, ISO 15189 clinical accreditation, and strong positioning within the European research and healthcare ecosystem.